Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

01/09/2022

Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari

DOI: 10.3390/cancers14174142

Full link: https://www.mdpi.com/2072-6694/14/17/4142

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Send us a message

Cura Project

Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study

Related Posts

In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”

Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)